Myeloperoxidase activity in blood plasma as a criterion of therapy for patients with cardiovascular disease

   
Grigorieva D.V.1, Gorudko I.V.1, Kostevich V.A.2, Sokolov A.V.2, Buko I.V.3, Vasilyev V.B.4, Polonetsky L.Z.5, Panasenko O.M.6 , Cherenkevich S.N.1

1. Belarusian State University, Minsk, Belarus
2. Institute for Experimental Medicine, Saint-Petersburg, Russia; Research Institute of Physical-Chemical Medicine, Moscow, Russia
3. Scientific practical centre of hygiene republican unitary enterprise, Minsk, Belarus
4. Institute for Experimental Medicine, Saint-Petersburg, Russia
5. Republican Science-Practical Center of Cardiology, Minsk, Belarus
6. Research Institute of Physical-Chemical Medicine, Moscow, Russia
Section: Clinical and Diagnostic Research
DOI: 10.18097/PBMC20166203318      PubMed Id: 27420626
Year: 2016  Volume: 62  Issue: 3  Pages: 318-324
A significant increase in the myeloperoxidase (MPO) activity has been found in plasma of patients with stable angina and with acute coronary syndrome (ACS) in comparison with the control group. MPO concentration was significantly increased in plasma of ACS patients. Reduced MPO activity in the treated ACS patients correlated with a favorable outcome of the disease. Generally, changes in plasma MPO concentration coincided with changes in lactoferrin concentration thus confirming the role of neutrophil degranulation in the increase of plasma concentrations of these proteins. The increase in MPO activity was obviously determined by modification of the MPO protein caused by reactive oxygen species and halogen in the molar ratio of 1 : 25 and 1 : 50. The decrease in plasma MPO activity may be associated with increased plasma concentrations of the physiological inhibitor of its activity, ceruloplasmin, and also with modification of the MPO protein with reactive oxygen species and halogen at their molar ratio of 1 : 100 and higher. Thus, MPO activity may be used for evaluation of effectiveness of the treatment of cardiovascular diseases.
Download PDF:
Keywords: myeloperoxidase, acute coronary syndrome, peroxidase activity, neutrophils, ceruloplasmin, lactoferrin
Citation:

Grigorieva, D. V., Gorudko, I. V., Kostevich, V. A., Sokolov, A. V., Buko, I. V., Vasilyev, V. B., Polonetsky, L. Z., Panasenko, O. M., Cherenkevich, S. N. (2016). Myeloperoxidase activity in blood plasma as a criterion of therapy for patients with cardiovascular disease. Biomeditsinskaya khimiya, 62(3), 318-324.
This paper is also available as the English translation: 10.1134/S1990750816020050
References  
 2022 (vol 68)
 2021 (vol 67)
 2020 (vol 66)
 2019 (vol 65)
 2018 (vol 64)
 2017 (vol 63)
 2016 (vol 62)
 2015 (vol 61)
 2014 (vol 60)
 2013 (vol 59)
 2012 (vol 58)
 2011 (vol 57)
 2010 (vol 56)
 2009 (vol 55)
 2008 (vol 54)
 2007 (vol 53)
 2006 (vol 52)
 2005 (vol 51)
 2004 (vol 50)
 2003 (vol 49)